Abstract

High-risk neuromyelitis optica (NMO) syndrome is an inflammatory demyelinating disease characterized by the occurrence of bilateral and simultaneous optic neuritis without complete visual recovery or it occurs as an isolated episode of transverse myelitis accompanied by longitudinally extensive spinal cord lesions. On the other hand, Leber hereditary optic neuropathy (LHON) is a primarily hereditary disorder that affects all tissues of the body and its clinical presentation is tissue-specific for the optic nerve and, eventually, the spinal cord. Overlapping clinical features of neuromyelitis optica and Leber hereditary optic neuropathy may suggest common target organ diseases. The case report described herein emphasizes the coexistence of serum markers of both diseases, and suggests that further investigation of this challenging clinical presentation is warranted to confirm or rule out this association.

Keywords: Neuromyelitis optic; Optic atrophy, hereditary; Leber; Optic neuritis; DNA, mitochondrial; Mutation; Humans; Male; Adult; Case reports

INTRODUCTION

Neuromyelitis optica antibody (or aquaporin-4 antibody) is a well established serum marker associated to high-risk neuromyelitis optica syndrome that presents as an inflammatory demyelinating disease characterized by the occurrence of bilateral and simultaneous optic neuritis without complete visual recovery or it occurs as an isolated episode of transverse myelitis accompanied by longitudinally extensive spinal cord lesions. On the other hand, Leber hereditary optic neuropathy is a primarily hereditary disorder that affects all tissues of the body and its clinical presentation is tissue-specific for the optic nerve and, eventually, it might reach the spinal cord. Overlapping clinical features of neuromyelitis optica and Leber hereditary optic neuropathy may suggest common target organ diseases. The case report described herein emphasizes the coexistence of serum markers of both diseases, and suggests that further investigation of this challenging clinical presentation is warranted to confirm or rule out this association.

Keywords: Neuromyelitis optic; Optic atrophy, hereditary; Leber; Optic neuritis; DNA, mitochondrial; Mutation; Humans; Male; Adult; Case reports

ABSTRACT

Neuromyelitis optica antibody (or aquaporin-4 antibody) is a well-established serum marker associated to high-risk neuromyelitis optica syndrome that presents as an inflammatory demyelinating disease characterized by the occurrence of bilateral and simultaneous optic neuritis without complete visual recovery or it occurs as an isolated episode of transverse myelitis accompanied by longitudinally extensive spinal cord lesions. On the other hand, Leber hereditary optic neuropathy is a primarily hereditary disorder that affects all tissues of the body and its clinical presentation is tissue-specific for the optic nerve and, eventually, it might reach the spinal cord. Overlapping clinical features of neuromyelitis optica and Leber hereditary optic neuropathy may suggest common target organ diseases. The case report described herein emphasizes the coexistence of serum markers of both diseases, and suggests that further investigation of this challenging clinical presentation is warranted to confirm or rule out this association.

Keywords: Neuromyelitis optic; Optic atrophy, hereditary; Leber; Optic neuritis; DNA, mitochondrial; Mutation; Humans; Male; Adult; Case reports

INTRODUCTION

High-risk neuromyelitis optica (NMO) syndrome is an inflammatory demyelinating disease characterized by the occurrence of bilateral and simultaneous optic neuritis without complete visual recovery or it occurs as an isolated episode of transverse myelitis accompanied by longitudinally extensive spinal cord lesions. On the other hand, Leber hereditary optic neuropathy (LHON) is a primarily hereditary disorder due to mutations of mitochondrial DNA (mtDNA) that affects all tissues of the body and its clinical presentation is tissue-specific for the optic nerve and, eventually, the spinal cord. Overlapping clinical features may suggest that NMO and LHON are both organ-specific diseases. Interestingly, the association of multiple sclerosis (MS) and LHON has been documented, but few reports have evidenced the coexistence of NMO and LHON. To our knowledge, this is the first case of presumed high-risk syndrome for NMO, suggested by seropositivity of aquaporin-4 (AQP-4) antibody, occurring simultaneously with LHON. Only two classical NMO cases have been described before and they both describe patients with the complete spectrum of the disease (i.e. symptoms related to neuromyelitis and to optic neuritis), harboring LHON mtDNA mutations.

CASE REPORT

A 43-year-old man presented complaints of painless, subacute onset of blury vision in both eyes for two months. The right eye was first affected and the fellow eye became involved in the following week. He noted his vision was progressively worsening over time. He denied any other visual symptoms. Past ocular history included diabetes and hypertension. He had two maternal uncles with low vision.

He underwent a first neuro-ophtalmic consultation two months after onset of symptoms. The visual acuity was 20/200 OD and counting fingers at 3 feet OS. He identified 8/11 Ishihara color plates OD and 0/11 OS. There was a left relative afferent pupillary defect. Slit lamp examination was unremarkable. Fundoscopic examination revealed bilateral disc pallor (Figure 1). Neurologic examination was normal. Computerized visual fields revealed bitemporal hemianopia. A full ophthalmological examination confirmed the existence of heterolabia primary 11778 LHON mtDNA mutation. Other family members denied undergoing neuro-ophtalmic examination or any blood tests. Serum analyses including ANA, rheumatoid factor, VDRL, viral serologies, B12, and folate were all negative or unremarkable. However, there was a positive result for AQP-4 antibody (1:80) and a cerebrospinal fluid examination showed high total protein content (63 mg/dl) with no oligoclonal bands or pleocytosis. Brain and spinal cord MRI were normal. Not surprisingly, optical coherence tomography confirmed a profound bilateral decrease of the peripapillary retinal nerve fiber layer (Figure 3). He underwent a five-day course of intravenous methylprednisolone with no visual improvement.

Funding: No specific financial support was available for this study.

Disclosure of potential conflicts of interest: L.M.Simão is employee of Universidade Federal de Minas Gerais.

Correspondence address: Luciano M. Simão. Av. do Contorno, 4747 - Conj. 1705 - Belo Horizonte - MG - 30110-090 - Brazil - E-mail: lucianosimao@gmail.com

Submitted for publication: June 20, 2011
Accepted for publication: March 21, 2012
Study carried out at Institution: Visão Clínica Oftalmológica e Oftalmoclínica Rui Marinha.

1 Physician, Neuro-Ophthalmologist Universidade Federal de Minas Gerais - UFMG - Belo Horizonte (MG), Brazil.
DISCUSSION

Neuromyelitis optica has been distinguished from MS by the presence of optic neuritis that is usually bilateral, simultaneous, without complete visual recovery often followed by permanent visual loss. Clinical findings that are also suggestive of NMO are longitudinally extensive spinal cord lesions with absent or unspecific brain imaging abnormalities, and often rapid progression to debility, and even death[3,4].

High-risk syndrome for NMO should be suspected in isolated recurrent bilateral optic neuritis, or in recurring isolated longitudinally extensive myelitis[5]. Those patients are in high risk of developing the second index event that characterizes the full-spectrum of the disease. This syndrome is also recognized as forme fruste or limited form of NMO. To help confirm the diagnosis there is also a serum antibody marker available named aquaporin-4 antibody. It binds selectively to the AQP4 water channel, a protein complex located in the astrocytic foot processes at the blood brain barrier. Because of the location of the antigen, it might be considered not only a marker, but actually the causative agent[4]. It should be noted that anti-AQP4 is the first water channel specific autoantibody to be identified. AQP4 is considered the predominant water channel in the brain and spinal cord, and also in the skeletal muscles[4,5]. The localization of AQP4 in the spinal cord is consistent with the immunopathology of NMO, which involves inflammation at both the gray and white matter regions, and for unknown reasons, it is largely restricted to the spinal cord and optic nerves[5].

Figure 1. Funduscopic examination: severe bilateral optic disc pallor.

Figure 2. Computerized visual fields: OD cecocentral scotoma; OS absolute central scotoma.

Figure 3. Optical coherence tomography showed profound bilateral decrease of peripapillary retinal nerve fiber layer.
It has also been well documented that the human antigen assay of anti-AQP4 provides a sensitivity of 85%, and a specificity of 100% in cases of isolated transverse myelitis or in cases of isolated optic neuritis, which are suggestive of high-risk syndromes for NMO. In Brazil, the seroprevalence of anti-AQP4 test in NMO or high-risk syndrome for NMO patients was first reported in 2008 and the seropositivity in this group was 64.3%. This finding was similar to that observed in other countries.

Conversely, LHON is an mtDNA mutation disease whose clinical setting is confined to the optic nerve and, eventually, the spinal cord. Pathogenic mtDNA mutations occur mainly in the homoplasmic state (i.e. there is only mutant mtDNA within an individual). However, heteroplasmy is a mixture of a wild type and mutant mtDNA observed in about 15% of affected families.

It is worth remembering that the severity of visual loss and the optic atrophy are unpredictable despite the mutation load. This can be attributed to the impossibility of biopsying the target tissues (i.e. the optic nerve and retina) since the quantification of heteroplasy is currently available only from blood samples. Previous studies suggest the limited value of blood tests in predicting the degree of heteroplasmy in other tissues.

Although it has been suggested that the occurrence of 70% of mutant mtDNA in the blood of heteroplasmic individuals may contribute to optic atrophy, some reports have shown affected individuals with much lower mutation loads. It can be supposed that such patients should present enough mutant mtDNA load in the optic nerves to relapse the disease.

Seemingly NMO and LHON may share some clinical similarities but few reports have questioned the linkage between these diseases. Due to the paucity of LHON mtDNA mutation encountered in NMO patients, some studies have failed showing genetic correlation. However, this is the first case report to demonstrate NMO antibody in LHON, and probably, more similar cases will be reported as NMO antibody test has increasingly been ordered in medical practice.

In conclusion, the case described herein as painless, subacute bilateral decreased vision, and poor visual recovery, accompanied by maternal history of low vision and seropositivity of mtDNA mutation confirmed the diagnosis of LHON. Simultaneously the seropositivity of AQP-4 antibody suggests co-existence of a marker that labels individuals with NMO or high-risk syndrome for NMO. Whether this is a fact or mere coincidence only prospective studies would help confirm, or rule out, this striking correlation. Ophthalmologists and neurologists should bear in mind the possibility of this uncommon clinical association.

REFERENCES